At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 339 enrolled
Drug / intervention
Duloxetine hydrochloride - 40 mg +2 moredrug
Likely dose
Duloxetine hydrochloride - 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain
In Brief
A Phase 3 clinical trial evaluating Duloxetine hydrochloride - 40 mg, placebo, and 1 other intervention for Diabetic Neuropathies. Completed, enrolled 339 participants across 25 sites.
Detailed Summary
The purpose of the study is to determine if duloxetine can help patients with painful diabetic neuropathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Neuropathies
CountriesJapan
CollaboratorsShionogi
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartNov 2007
Primary CompletionMar 2009
TodayJul 2026
First PostedNov 1, 2007
Enrollment StartNov 1, 2007
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.7 years ago
Interventions
Duloxetine hydrochloride - 40 mgdrug
duloxetine 40 mg taken orally every day
placebodrug
placebo taken orally every day
Duloxetine hydrochloride - 60 mgdrug
duloxetine 60 mg taken orally every day